Overview

A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

To determine the efficacy of HS-25 (5, 10, 20 or 30 mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 4-week period of treatment in adults with primary hypercholesterolemia.

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang Hisun Pharmaceutical Co. Ltd.

Collaborator:

Covance